Barclays’s CalciMedica CALC Stock Holding History

Barclays’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-55	Closed	-$282	–	5430
2026 Q2	$282	Buy	+55	New	+$195	﹤0.01%	5070
2025 Q4	–	Sell	-11	Closed	-$175	–	5281
2025 Q3	$175	Buy	+11	New	+$158	﹤0.01%	5247

Other funds holding CALC

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Barclays's CALC Position: Q3 2026 in Review

Barclays sold out of CalciMedica (CALC) in Q3 2026, closing a stake of 55 shares — an estimated $282 sold.

Barclays first reported a position in CALC in Q3 2025 and held it in 2 quarters. The position peaked at $282 in Q2 2026. 3 funds tracked by Wall St. Rank hold CALC as of Q3 2026.

Barclays reported no remaining CalciMedica position as of Q3 2026 after selling out during the quarter.
Barclays sold 55 CalciMedica shares in Q3 2026, an estimated $282.
Barclays first reported a position in CalciMedica in Q3 2025 and held it in 2 quarters.
Barclays's CalciMedica position peaked at $282 in Q2 2026.
3 funds tracked by Wall St. Rank held CalciMedica as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.